Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

HMS faculty, help us improve the algorithms in Profiles by uploading your CV!

Samia Joseph Khoury, M.D.

Co-Author

This page shows the publications co-authored by Samia Khoury and Mohamed Sayegh.
Connection Strength

2.491
  1. The roles of the new negative T cell costimulatory pathways in regulating autoimmunity. Immunity. 2004 May; 20(5):529-38.
    View in: PubMed
    Score: 0.279
  2. Th1 cytokines, programmed cell death, and alloreactive T cell clone size in transplant tolerance. J Clin Invest. 2002 Jun; 109(11):1471-9.
    View in: PubMed
    Score: 0.245
  3. Ex vivo treatment of antigen-presenting cells with CTLA4Ig and encephalitogenic peptide prevents experimental autoimmune encephalomyelitis in the Lewis rat. J Immunol. 1996 Oct 15; 157(8):3700-5.
    View in: PubMed
    Score: 0.166
  4. Distinct functions of autoreactive memory and effector CD4+ T cells in experimental autoimmune encephalomyelitis. Am J Pathol. 2008 Aug; 173(2):411-22.
    View in: PubMed
    Score: 0.093
  5. Differential role of programmed death-ligand 1 [corrected] and programmed death-ligand 2 [corrected] in regulating the susceptibility and chronic progression of experimental autoimmune encephalomyelitis. J Immunol. 2006 Mar 15; 176(6):3480-9.
    View in: PubMed
    Score: 0.080
  6. A critical role for the programmed death ligand 1 in fetomaternal tolerance. J Exp Med. 2005 Jul 18; 202(2):231-7.
    View in: PubMed
    Score: 0.076
  7. Assessment by flow cytometry of intracellular cytokine production in the peripheral blood cells of renal transplant recipients. Clin Transplant. 2004 Aug; 18(4):395-401.
    View in: PubMed
    Score: 0.071
  8. Neural stem/progenitor cells express costimulatory molecules that are differentially regulated by inflammatory and apoptotic stimuli. Am J Pathol. 2004 May; 164(5):1615-25.
    View in: PubMed
    Score: 0.070
  9. Defining Th1 and Th2 immune responses in a reciprocal cytokine environment in vivo. J Immunol. 2004 Apr 01; 172(7):4260-5.
    View in: PubMed
    Score: 0.069
  10. Regulatory functions of CD8+CD28- T cells in an autoimmune disease model. J Clin Invest. 2003 Oct; 112(7):1037-48.
    View in: PubMed
    Score: 0.067
  11. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med. 2003 Jul 07; 198(1):63-9.
    View in: PubMed
    Score: 0.066
  12. Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J Exp Med. 2003 Jul 07; 198(1):71-8.
    View in: PubMed
    Score: 0.066
  13. Effect of targeted disruption of STAT4 and STAT6 on the induction of experimental autoimmune encephalomyelitis. J Clin Invest. 2001 Sep; 108(5):739-47.
    View in: PubMed
    Score: 0.058
  14. T cell costimulatory blockade as a novel immune intervention in autoimmune diseases. Clin Dermatol. 2001 Sep-Oct; 19(5):586-91.
    View in: PubMed
    Score: 0.058
  15. Regulatory functions of self-restricted MHC class II allopeptide-specific Th2 clones in vivo. J Clin Invest. 2001 Apr; 107(7):909-16.
    View in: PubMed
    Score: 0.056
  16. CD28-independent induction of experimental autoimmune encephalomyelitis. J Clin Invest. 2001 Mar; 107(5):575-83.
    View in: PubMed
    Score: 0.056
  17. The role of CD154-CD40 versus CD28-B7 costimulatory pathways in regulating allogeneic Th1 and Th2 responses in vivo. J Clin Invest. 2000 Jul; 106(1):63-72.
    View in: PubMed
    Score: 0.054
  18. Role of passive T-cell death in chronic experimental autoimmune encephalomyelitis. J Clin Invest. 2000 Apr; 105(8):1109-16.
    View in: PubMed
    Score: 0.053
  19. Costimulatory signal blockade in murine relapsing experimental autoimmune encephalomyelitis. J Neuroimmunol. 1999 May 03; 96(2):158-66.
    View in: PubMed
    Score: 0.049
  20. Acquired thymic tolerance: role of CTLA4 in the initiation and maintenance of tolerance in a clinically relevant autoimmune disease model. J Immunol. 1999 Jan 15; 162(2):761-5.
    View in: PubMed
    Score: 0.048
  21. Blocking costimulatory signals to induce transplantation tolerance and prevent autoimmune disease. Int Rev Immunol. 1999; 18(3):185-99.
    View in: PubMed
    Score: 0.048
  22. Kinetics of expression of costimulatory molecules and their ligands in murine relapsing experimental autoimmune encephalomyelitis in vivo. J Immunol. 1998 Aug 01; 161(3):1104-12.
    View in: PubMed
    Score: 0.047
  23. Mechanisms of indirect allorecognition: characterization of MHC class II allopeptide-specific T helper cell clones from animals undergoing acute allograft rejection. Transplantation. 1998 Apr 15; 65(7):876-83.
    View in: PubMed
    Score: 0.046
  24. Mechanisms of acquired thymic tolerance in vivo: intrathymic injection of antigen induces apoptosis of thymocytes and peripheral T cell anergy. J Immunol. 1998 Feb 01; 160(3):1504-8.
    View in: PubMed
    Score: 0.045
  25. Differential effects of B7-1 blockade in the rat experimental autoimmune encephalomyelitis model. J Immunol. 1997 Nov 01; 159(9):4212-6.
    View in: PubMed
    Score: 0.045
  26. In vivo mechanisms of acquired thymic tolerance. Cell Immunol. 1997 Aug 01; 179(2):165-73.
    View in: PubMed
    Score: 0.044
  27. Class II MHC allopeptide-specific T-cell clones transfer delayed type hypersensitivity responses in vivo. Transplant Proc. 1997 Feb-Mar; 29(1-2):1008-9.
    View in: PubMed
    Score: 0.042
  28. Mechanisms of indirect allorecognition in graft rejection: class II MHC allopeptide-specific T cell clones transfer delayed-type hypersensitivity responses in vivo. Transplantation. 1996 Sep 27; 62(6):705-10.
    View in: PubMed
    Score: 0.041
  29. Mechanisms of oral tolerance by MHC peptides. Ann N Y Acad Sci. 1996 Feb 13; 778:338-45.
    View in: PubMed
    Score: 0.040
  30. CD28-B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system. J Immunol. 1995 Nov 15; 155(10):4521-4.
    View in: PubMed
    Score: 0.039
  31. Mechanisms of acquired thymic tolerance in experimental autoimmune encephalomyelitis: thymic dendritic-enriched cells induce specific peripheral T cell unresponsiveness in vivo. J Exp Med. 1995 Aug 01; 182(2):357-66.
    View in: PubMed
    Score: 0.038
  32. Differential effects of oral versus intrathymic administration of polymorphic major histocompatibility complex class II peptides on mononuclear and endothelial cell activation and cytokine expression during a delayed-type hypersensitivity response. Am J Pathol. 1994 Jun; 144(6):1149-58.
    View in: PubMed
    Score: 0.035
  33. Acquired tolerance to experimental autoimmune encephalomyelitis by intrathymic injection of myelin basic protein or its major encephalitogenic peptide. J Exp Med. 1993 Aug 01; 178(2):559-66.
    View in: PubMed
    Score: 0.033
  34. Induction of immunity and oral tolerance to alloantigen by polymorphic class II major histocompatibility complex allopeptides in the rat. Transplant Proc. 1993 Feb; 25(1 Pt 1):357-8.
    View in: PubMed
    Score: 0.032
  35. In vitro and in vivo studies of IgG-derived Treg epitopes (Tregitopes): a promising new tool for tolerance induction and treatment of autoimmunity. J Clin Immunol. 2013 Jan; 33 Suppl 1:S43-9.
    View in: PubMed
    Score: 0.031
  36. Induction of immunity and oral tolerance with polymorphic class II major histocompatibility complex allopeptides in the rat. Proc Natl Acad Sci U S A. 1992 Aug 15; 89(16):7762-6.
    View in: PubMed
    Score: 0.031
  37. Differential engagement of Tim-1 during activation can positively or negatively costimulate T cell expansion and effector function. J Exp Med. 2007 Jul 09; 204(7):1691-702.
    View in: PubMed
    Score: 0.022
  38. The cell cycle associated protein, HTm4, is expressed in differentiating cells of the hematopoietic and central nervous system in mice. J Mol Histol. 2005 Feb; 36(1-2):77-87.
    View in: PubMed
    Score: 0.018
  39. Specific MDR1 P-glycoprotein blockade inhibits human alloimmune T cell activation in vitro. J Immunol. 2001 Feb 15; 166(4):2451-9.
    View in: PubMed
    Score: 0.014
  40. Immune parameters affecting adenoviral vector gene therapy in the brain. J Neurovirol. 1998 Apr; 4(2):194-203.
    View in: PubMed
    Score: 0.011
  41. Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Annu Rev Immunol. 1994; 12:809-37.
    View in: PubMed
    Score: 0.009
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.